Published on : Aug 02, 2016
ALBANY, New York, August 02, 2016 - Market Research Hub has added a new report, titled ‘Retinopathy - Pipeline Review, H1 2016,’ to its offering. This report on the retinopathy market has been compiled by conducting both primary and secondary research and analyzes the market on the basis of its pipeline review. A snapshot of the therapeutics used for the prevention of retinopathy has also been presented under this report. The pharmacological action of the employed therapeutics, their development history, and the latest news also form an integral part of this study. The pipeline products described in this report have been analyzed on the basis of their development stage i.e. from pre-registration to discovery.
The first section of the report presents an overview of the retinopathy market. This section highlights the development of therapeutics, pipeline products utilized in retinopathy, and a comparative analysis of these pipeline products. Retinopathy refers to acute or persistent damage to the retina and may develop when vascular remodeling or continuous inflammation of the retina takes place over a period of time.
Retinopathy can also be an ocular manifestation of systemic diseases, as in the case of hypertension or diabetes. Thus, a number of diseases can result in retinopathy with either a complete or partial loss of vision. There are number of types of retinopathy, such as diabetic retinopathy, retinopathy of prematurity (ROP), central serious retinopathy, and hypertensive retinopathy. The symptoms of this disease may not come into notice till its late stages and may include sudden vision loss in either or both eyes, blurred vision, flashing lights, black spots, and difficulty in reading.
In the next part of the report, the therapeutics still under development by both universities and companies have been presented. Moving further, the clinical late stage and early stage products have been analyzed in this study. The drug profiles, their mechanism of action, and their research and development progress have also been encapsulated in this study.
Moving further, the key dynamics impacting the development of the retinopathy market have also been compiled in this study. The increasing geriatric population and the growing demand for safe and cost-effective treatment options are amongst the prime factors fuelling the growth of the market. In addition, the improvement in healthcare infrastructure globally will also positively impact the development of the market.
Furthermore, the rising initiatives taken by several governments for increasing awareness amongst patients to encourage regular retinal checkups for the prevention of permanent visual impairment will also stimulate the growth of the global retinopathy market.
Click here to get more info with TOC in a PDF Format: https://www.marketresearchhub.com/enquiry.php?type=S&repid=746162
In the following section of this study, updates on the recent pipelines, dormant projects, and discontinued products in the retinopathy market have been detailed. The vendor landscape section of the report throws light on the companies excelling in pipeline products in the market for radiotherapy. These are Acucela Inc., Biomar Microbial Technologies, Biophytis SAS, Edison Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., Insmed Incorporated, Navigen Pharmaceuticals, Inc., and RedHill Biopharma Ltd., among others.
About Market Research Hub
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
For Enquiries, Call :
+1-800-998-4852US Toll Free
Email : email@example.com